Everyone's heard about Ozempic, Wegovy, and Mounjaro by now. But how much is Medicare actually spending on these drugs, and how fast is it growing? That's what this dataset is about.
I pulled together state-by-state Medicare Part D spending data on GLP-1 medications going back to 2017, when Ozempic first got FDA approval. The dataset covers all 50 states and territories through 2023 at the state level, plus provisional 2024 and 2025 national… See the full description on the dataset page:
https://huggingface.co/datasets/sbreitenbach/cms-glp1-data.
